Acadia Pharmaceuticals, Inc. (ACAD) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $26.41 --0%
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
NEOV, MANU, CTAS, More
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)
- Increasing unusual option volume: ACAD ALHC PLAY FPS ITUB NAVN WVE UAL XEL
- LuxExperience B.V. (LUXE) Misses Q2 EPS by 11c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
